Welcome by Bhawna Sirohi, Sharat Damodar, Devi Shetty
Speaker : Bhawna Sirohi, Sharat Damodar, Devi Shetty
Plenary : Landmark advances in the management of breast cancer over the last Decade: Where will we be in 2025?
Speaker : Eric Winer, Harvard University, Boston, USA
Plenary : Adjuvant Endocrine Therapy: Replacing chemotherapy with endocrine therapy: is this an achievable goal?
Speaker : Ian E. Smith, Royal Marsden Hospital, London, UK
Risk reducing strategies among women at high risk of developing breast cancer: can we define risk accurately?
Moderator : Sudeep Gupta, Tata Memorial Centre, Mumbai
Plenary : Optimal sequencing of anti her2 therapy in the metastatic setting? - Practical recommendations in situations with limited access to all approved agents
Speaker : Clifford Hudis, Memorial Sloan Kettering Cancer Centre, New York, USA
Speaker : Nita Nair, Tata Memorial Centre, Mumbai
Biomakers in breast cancer : Rational use and clinical implications
Moderator : BK Smruti, Bombay Hospital, Mumbai
Plenary : Do bone modifying agents reducing the risk of breast cancer recurrence: putting EBCCTG data into perspective
Speaker : Trevor Powles, Parkside Cancer Centre,Wimbledon, UK
Study 1 : Weight loss in breast cancer survivors can improve outcomes
Speaker : Rosina Ahmed, Tata Memorial Centre, Kolkata
Study 2 : Development of a microfluidics-based platform for detecting and isolating CTCs
Speaker : Rahul Purwar, Indian Institute of Technology, Mumbai
Study 3 : Randomised trial of adjuvant metronomic chemotherapy in patients with locally advanced Triple negative breast cancer
Speaker : Shona Nag, Jehangir Hospital, Pune
Study 4: Randomised Phase II trial to evaluate the benefit of predictive genetic markers in treatment of breast cancer in the neo adjuvant setting
Speaker : Sudeep Gupta, Tata Memorial Centre, Mumbai
Study 5 : Smart trigger responsive, targeted nanocapsules for oral delivery of paclitaxel, resveratrol and Vitamin D in triple negative breast cancer
Speaker : Rinti Banerjee, Indian Institute of Technology, Mumbai
Debate : Trials are now warranted of surgery vs. none as part of the curative treatment for early breast cancer
Session on Health Economics
Moderator : CS Pramesh, Tata Memorial Centre, Mumbai
Plenary : Novel therapeutic approaches to women with metastatic TNBC: 2015 has been a great year!
Speaker : Ian E. Krop, Dana Faber Cancer Institute, Harvard University, Boston, USA
Debate : pCR - a surrogate for survival - should we aim for it ?
Debate : Sentinel node positive in Breast conserving surgery - treating the axilla
Speaker : Rahul Krishnatry, Bengaluru; Sandeep Jain, Bengaluru Axillary clearance is a must: Somashekhar SP, Manipal Hospital, Bengaluru Radiotherapy in enough: Sanjoy Chatterjee, Tata Memorial Centre, Kolkata
Moderator : Shaheenah Dawood, Dubai Hospital, UAE Vineet Gupta, Sakra World Hospital, Bengaluru